MXPA04005105A - Formulaciones de acitromicina directamente compresibles. - Google Patents

Formulaciones de acitromicina directamente compresibles.

Info

Publication number
MXPA04005105A
MXPA04005105A MXPA04005105A MXPA04005105A MXPA04005105A MX PA04005105 A MXPA04005105 A MX PA04005105A MX PA04005105 A MXPA04005105 A MX PA04005105A MX PA04005105 A MXPA04005105 A MX PA04005105A MX PA04005105 A MXPA04005105 A MX PA04005105A
Authority
MX
Mexico
Prior art keywords
azithromycin
tablet
dry blend
mga
pharmaceutically acceptable
Prior art date
Application number
MXPA04005105A
Other languages
English (en)
Inventor
William Collier Steven
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MXPA04005105A publication Critical patent/MXPA04005105A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere a una mezcla en seco, utilizada para formar comprimidos de acitromicina por compresion directa, que comprende acitromicina no dihidratada y al menos un excipiente farmaceuticamente aceptable.Esta invencion se refiere tambien a un comprimido de acitromicina que comprende acitromicina no dihidratada y al menos un excipiente farmaceuticamente aceptable. Preferiblemente, el comprimido de acitromicina se forma mediante compresion directa de la mezcla en seco, de la presente invencion, para formar dicho comprimido de acitromicina.Preferiblemente, el comprimido de acitromicina, de la presente invencion, contiene una dosificacion de 250 mgA, 500 mgA o 600 mgA de acitromicina.Esta invencion se refiere ademas a un comprimido de acitromicina que se produce formando una mezcla en seco de una forma A de acitromicina no granulada, y al menos un excipiente farmaceuticamente aceptable. El comprimido de acitromicina se forma a continuacion mediante compresion directa de la mezcla en seco.
MXPA04005105A 2001-12-21 2002-12-09 Formulaciones de acitromicina directamente compresibles. MXPA04005105A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34348001P 2001-12-21 2001-12-21
PCT/IB2002/005222 WO2003053416A1 (en) 2001-12-21 2002-12-09 Directly compressible formulations of azithromycin

Publications (1)

Publication Number Publication Date
MXPA04005105A true MXPA04005105A (es) 2004-08-19

Family

ID=23346277

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04005105A MXPA04005105A (es) 2001-12-21 2002-12-09 Formulaciones de acitromicina directamente compresibles.

Country Status (20)

Country Link
US (4) US20030165563A1 (es)
EP (1) EP1455758A1 (es)
JP (1) JP2005513099A (es)
KR (1) KR100632339B1 (es)
CN (1) CN1668282A (es)
AR (1) AR037930A1 (es)
AU (1) AU2002348884A1 (es)
BR (1) BR0215193A (es)
CA (1) CA2469246A1 (es)
IL (1) IL161996A0 (es)
MX (1) MXPA04005105A (es)
NO (1) NO20043110L (es)
NZ (1) NZ532707A (es)
PA (1) PA8562201A1 (es)
PE (1) PE20030591A1 (es)
PL (1) PL371259A1 (es)
RU (1) RU2277914C2 (es)
TW (1) TW200301138A (es)
WO (1) WO2003053416A1 (es)
ZA (1) ZA200403486B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020231A2 (en) * 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
AU2002348884A1 (en) * 2001-12-21 2003-07-09 Pfizer Products Inc. Directly compressible formulations of azithromycin
FR2834889B1 (fr) * 2002-01-18 2004-04-02 Roquette Freres Forme pharmaceutique solide orodispersible
GB0211620D0 (en) * 2002-05-21 2002-07-03 Bioprogress Technology Ltd Powder compaction and enrobing
US20030228370A1 (en) * 2002-06-11 2003-12-11 Michel Serpelloni Orodispersible solid pharmaceutical form
HRP20020614A2 (en) * 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
WO2005002592A2 (en) * 2003-07-01 2005-01-13 Ranbaxy Laboratories Limited Stable oral compositions of azithromycin monohydrate
WO2005004919A2 (en) * 2003-07-02 2005-01-20 Eurand, Inc. Extended release systems for macrolide antibiotics
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
US20050101547A1 (en) * 2003-11-06 2005-05-12 Sadatrezaei Mohsen Stabilized azithromycin composition
BRPI0417348A (pt) * 2003-12-04 2007-03-13 Pfizer Prod Inc processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo
EP1691786A1 (en) 2003-12-04 2006-08-23 Pfizer Products Inc. Multiparticulate compositions with improved stability
EP1694304A2 (en) * 2003-12-04 2006-08-30 Pfizer Products Inc. Azithromycin multiparticulate dosage forms by liquid-based processes
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
SI1691787T1 (sl) 2003-12-04 2008-10-31 Pfizer Prod Inc Postopek za pripravo farmacevtskih produktov iz več delcev
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
JP2008524318A (ja) * 2004-12-21 2008-07-10 ファイザー・プロダクツ・インク 安定なアジスロマイシン非二水和物の経口用懸濁液剤
US7901710B2 (en) * 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
TWI482772B (zh) * 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
WO2008024044A1 (en) * 2006-08-21 2008-02-28 Astrazeneca Ab Compositions, suitable for oral administration, comprising a triazolo [4, 5] pyrimidin derivate
CA2671727C (en) * 2006-12-20 2016-02-16 Genpharm Ulc A composition containing a bisphosphonic acid in combination with vitamin d
CN101772304B (zh) * 2007-07-31 2014-07-09 卡吉尔公司 直接可压缩的右旋糖
WO2009059605A1 (en) * 2007-11-08 2009-05-14 University Of Copenhagen Small scale solid state screening
PT2266582E (pt) * 2008-03-18 2015-09-04 Aleksander Vladimirovich Dikovskiy Composição farmacêutica para a prevenção da disbiose associada à administração enteral de antibióticos
EP2266581B1 (en) * 2008-03-18 2015-09-23 Dikovskiy, Aleksander Vladimirovich Pharmaceutical composition of antibiotics and prebiotics for preventing and treating dysbiosis during antibacterial therapy
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
AR083417A1 (es) * 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
KR20150092385A (ko) 2014-02-03 2015-08-13 씨제이헬스케어 주식회사 솔리페나신을 포함하는 안정한 제제 및 이의 제조방법
US20150242978A1 (en) 2014-02-24 2015-08-27 Mindojo Ltd. Content development and moderation flow for e-learning datagraph structures
US20160145548A1 (en) * 2014-11-20 2016-05-26 The Procter & Gamble Company Cleaning composition refill for an automatic dishwasher dispensing device
CN105193753A (zh) * 2015-10-30 2015-12-30 成都通德药业有限公司 一种阿奇霉素分散片的制备方法
CN110633487B (zh) * 2019-07-03 2023-03-14 北京中医药大学 直接压片的片剂处方的设计方法
CN111467362B (zh) * 2020-05-09 2021-07-06 北京四环制药有限公司 一种阿奇霉素药用组合物及其制备方法和其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
RO107257B1 (ro) * 1987-07-09 1993-10-30 Pfizer Procedeu de obtinere a unui dihidrat de azitromicina, cristalin
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
TW271400B (es) * 1992-07-30 1996-03-01 Pfizer
KR970702725A (ko) * 1994-04-26 1997-06-10 노부히로 나리따 비소세포 폐암 치료용 의약 조성물(Medicinal Composition as a Remedy for Nonsmall Cell Lung Cancer)
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
DK0758244T4 (da) * 1994-05-06 2008-06-16 Pfizer Doseringsformer af azithromycin med styret frigivelse
IL119866A (en) 1996-12-19 1999-12-31 Unipharm Ltd Antibiotic tablet
CO4920215A1 (es) 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
US6339063B1 (en) * 1997-09-10 2002-01-15 Merck & Co., Inc. 9a-azalides as veterinary antimicrobial agents
JP2001515865A (ja) * 1997-09-10 2001-09-25 メルク エンド カムパニー インコーポレーテッド 家畜抗菌剤としての９ａ−アザライド
CA2245398C (en) * 1998-08-21 2002-01-29 Apotex Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
IL143376A0 (en) * 1998-11-30 2002-04-21 Teva Pharma Ethanolate of azithromycin, process for the manufacture, and pharmaceutical compositions thereof
FR2793690B1 (fr) * 1999-03-30 2003-01-03 Cll Pharma Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
ES2177373B1 (es) 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
AU2001214115A1 (en) 2000-08-01 2002-02-13 Habil F. Khorakiwala Process for the preparation of anhydrous azithromycin
US6861413B2 (en) * 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
JP2004530703A (ja) * 2001-05-22 2004-10-07 ファイザー・プロダクツ・インク 結晶形アジスロマイシン
WO2003032922A2 (en) * 2001-10-18 2003-04-24 Teva Pharmaceutical Industries Ltd. Stabilized azithromycin compositions
JP2005515212A (ja) * 2001-12-21 2005-05-26 ファイザー・プロダクツ・インク アジスロマイシンの湿式造粒法
AU2002348884A1 (en) * 2001-12-21 2003-07-09 Pfizer Products Inc. Directly compressible formulations of azithromycin
KR100676025B1 (ko) * 2002-02-01 2007-01-29 화이자 프로덕츠 인코포레이티드 아지쓰로마이신의 건조 과립화 제제

Also Published As

Publication number Publication date
AU2002348884A1 (en) 2003-07-09
TW200301138A (en) 2003-07-01
CA2469246A1 (en) 2003-07-03
US20060024364A1 (en) 2006-02-02
PE20030591A1 (es) 2003-07-12
AR037930A1 (es) 2004-12-22
PL371259A1 (en) 2005-06-13
US20030165563A1 (en) 2003-09-04
KR100632339B1 (ko) 2006-10-12
KR20040066175A (ko) 2004-07-23
RU2277914C2 (ru) 2006-06-20
PA8562201A1 (es) 2003-07-28
NO20043110L (no) 2004-07-20
US20060024363A1 (en) 2006-02-02
NZ532707A (en) 2006-07-28
BR0215193A (pt) 2004-11-16
EP1455758A1 (en) 2004-09-15
RU2004118709A (ru) 2005-04-20
CN1668282A (zh) 2005-09-14
US20050287209A1 (en) 2005-12-29
US7070811B2 (en) 2006-07-04
IL161996A0 (en) 2005-11-20
WO2003053416A1 (en) 2003-07-03
ZA200403486B (en) 2006-05-31
JP2005513099A (ja) 2005-05-12

Similar Documents

Publication Publication Date Title
MXPA04005105A (es) Formulaciones de acitromicina directamente compresibles.
CA2311734A1 (en) Flash-melt oral dosage formulation
HK1067544A1 (en) Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
MY114776A (en) Fluoxetine pharmaceutical formulations
TW200633730A (en) Oral disintegrating dosage forms
AU3846901A (en) Oral, nasal and pulmonary dosage formualtions of copolymer 1
NZ507566A (en) Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
MXPA03010549A (es) Formas de dosificacion de oxcarbazepina.
PL364598A1 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
BG103714A (en) Pararacetamol-containing tablet
GB0012362D0 (en) Chemical compounds
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
ZA200308353B (en) Compaction process for manufacture of sodium phenytoin dosage form.
ATE441410T1 (de) Fenofibrattabletten
IL150528A0 (en) Ibuprofen containing active agent preparation
MXPA04003346A (es) Formulacion de dosis oral de disolucion instantanea.
AP2004003045A0 (en) Preparation compositions containing acid-unstable physiologically active compounds and process for producing the same.
MY136059A (en) Swallow tablet comprising paracetamol
IL157065A0 (en) 2h-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
HUP0301072A2 (hu) Hatóanyagként 4-amino-1-(hidroxi-butilidén)-1,1-biszfoszfonsavat tartalmazó, közvetlen tablettázással előállított tabletta
GB9914936D0 (en) Directly compressible starch as enhancer of properties of excipients when used as binder and disintegrant for compression tablets
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
EP0427124A3 (en) Antacid tablets
NZ332545A (es)
GB0001315D0 (en) Organic compounds

Legal Events

Date Code Title Description
FA Abandonment or withdrawal